Analysis of Unsubstantiated FDA Approval Claim for LMMY and Related Market Dynamics

The analysis centers on a Reddit post claiming $LMMY received FDA approval after hours on November28,2025, alongside conflicting discussion points: bearish sentiment on the weekly chart, clarification that Orphan Drug Designation (ODD) is distinct from full FDA approval for commercialization, and appreciation for shared due diligence [3]. Key findings include:

1. Corporate Realignment
   : Exousia Pro, Inc. (OTCID:MAJI) acquired a 51% controlling stake in $LMMY via an all-stock transaction for its subsidiary Exousia AI on November17, aiming to establish an SEC-reporting entity for non-dilutive capital access and branding improvements [2].
2. Unsubstantiated Approval Claim
   : No official FDA approval for commercialization was found for $LMMY or Exousia Pro/Bio in verified sources (SEC filings, press releases, or reputable news outlets) [0,1,2]. The Reddit claim lacks supporting evidence.
3. Stock Performance
   : $LMMY (pink sheet stock) closed at $0.68 on November30, down3.57% with extremely low volume (272 shares). Recent volatility (10% drop on Nov26,2.86% gain on Nov28) aligns with the bearish weekly chart comment [0].
4. ODD vs Full Approval
   : The discussion correctly notes ODD (a designation offering perks) is not equivalent to full FDA approval for commercialization [3].

• Misinformation Risk
  : The unsubstantiated FDA approval claim highlights potential misinformation in retail investor discussions, emphasizing the need for verification via official channels [3].
• Low Float Impact
  : $LMMY has a low float (2.53M unrestricted shares) due to77.97M restricted shares (including MAJI’s51% stake), contributing to price volatility [2].
• Strategic Uplisting Plan
  : The Reddit post mentions $LMMY’s intent to pursue NASDAQ uplisting, a key strategic goal post-realignment [3].
• Clinical Pipeline Gap
  : Exousia Pro is a clinical-stage biotech, but no details on active trials or FDA review status were found, indicating a need for further transparency [2].

• Misinformation
  : Unverified claims may lead to uninformed investment decisions [3].
• Pink Sheet Risks
  : Limited regulatory oversight and low liquidity increase investment risk [0].
• Volatility
  : Low float and unsubstantiated claims can trigger significant price swings [0,2].

• NASDAQ Uplisting
  : Successful uplisting could improve liquidity and investor access [3].
• Clinical Pipeline
  : Progress in Exousia’s exosome-based delivery systems may enhance long-term value (though no current trial details are available) [2].

• $LMMY is a pink sheet stock with a market cap of $5.25M, EPS of $0.01, and P/E ratio of67.50 [0].
• No official FDA approval for commercialization exists; the Reddit claim is unsubstantiated [0,1,2].
• Exousia Pro’s 51% stake acquisition aims to realign $LMMY as an SEC-reporting entity [2].
• ODD is a designation, not full approval; investors should distinguish between the two [3].